-
公开(公告)号：US07833971B2
公开(公告)日：2010-11-16
申请号：US12001494
申请日：2007-12-10
Applicant: Asya Grinberg , John Knopf , Ravindra Kumar , Jasbir Seehra
Inventor： Asya Grinberg , John Knopf , Ravindra Kumar , Jasbir Seehra
IPC: C07K14/00
CPC classification number: C07K14/475 , A61K38/00 , A61K38/179
Abstract: The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
Abstract translation: 本公开涉及用于治疗与肌生成抑制素，结节和GDF-11相关的多种疾病的Cerberus / Coco多肽或其变体。
-
公开(公告)号：US20100183624A1
公开(公告)日：2010-07-22
申请号：US12657146
申请日：2010-01-13
Applicant: Jasbir Seehra , Ravindra Kumar , Jennifer Lachey , Alan Koncarevic
Inventor： Jasbir Seehra , Ravindra Kumar , Jennifer Lachey , Alan Koncarevic
IPC: A61K38/02 , A61K39/395 , A61K31/7088 , A61P5/00 , A61P3/10
CPC classification number: C07K16/40 , A61K31/00 , A61K31/7088 , A61K38/179 , A61K2039/505 , C07K14/705 , C07K16/22 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2319/30
Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.
Abstract translation: 在某些方面，本发明提供了通过施用ActRIIB信号通路的拮抗剂来增加有需要的患者中的脂连蛋白的组合物和方法。 此类拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗激活素A和/或B抗体，抗肌生成抑制素抗体，抗GDF3抗体和抗BMP7抗体。 还提供了用于改善一种或多种不期望的抗雄激素治疗效果的方法，包括肌肉损失，骨丢失，增加的肥胖和/或增加的胰岛素抵抗。 可以通过引起循环中脂联素浓度的增加来治疗多种疾病。
-
23.发明申请ANTAGONISTS OF BMP9, BMP10, ALK1 AND OTHER ALK1 LIGANDS, AND USES THEREOF 有权BMP9，BMP10，ALK1和其他ALK1配体的拮抗剂及其用途公开(公告)号：US20090304691A1
公开(公告)日：2009-12-10
申请号：US12467170
申请日：2009-05-15
Applicant: Jasbir Seehra , John Knopf , Robert S. Pearsall , Asya Grinberg , Ravindra Kumar
Inventor： Jasbir Seehra , John Knopf , Robert S. Pearsall , Asya Grinberg , Ravindra Kumar
IPC: A61K39/395 , C07K16/18 , A61K31/7088 , A61K31/7105 , A61K38/16 , A61P35/00
CPC classification number: C07K16/22 , A61K9/0048 , A61K38/1709 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/47 , C07K14/71 , C07K2317/24 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
Abstract translation: 在某些方面，本公开涉及以下认识：包含活化素样激酶I（ALK1）多肽的细胞外结构域的配体结合部分的多肽可用于抑制体内血管发生，特别是在血管生成相关的哺乳动物中 疾病 在某些方面，本公开表明BMP9和/或BMP10的拮抗剂，ALK1的配体也可用于抑制体内血管发生。
-
公开(公告)号：US07612040B2
公开(公告)日：2009-11-03
申请号：US11479181
申请日：2006-06-30
Applicant: John Knopf , Jasbir Seehra , Ravindra Kumar
Inventor： John Knopf , Jasbir Seehra , Ravindra Kumar
CPC classification number: C07K14/47 , A61K38/00 , C07K14/495
Abstract: The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders.
Abstract translation: 本公开涉及Lefty衍生物和Lef多肽作为某些配体如Nodal，GDF-8（Myostatin）和GDF-11功能的拮抗剂的用途。 这些衍生物可以与其它功能异源蛋白如IgG，特别是IgG的Fc部分融合。 根据该公开内容，Lefty多肽可用于治疗各种疾病，包括例如神经元疾病，肌肉和骨骼状况以及代谢紊乱。
-
公开(公告)号：US10059756B2
公开(公告)日：2018-08-28
申请号：US13447091
申请日：2012-04-13
Applicant: Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra , Kristian Pietras
Inventor： Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra , Kristian Pietras
CPC classification number: C07K14/71 , C07K2319/30 , C07K2319/32
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
-
Patent Agency Ranking
公开(公告)号：US08455428B2
公开(公告)日：2013-06-04
申请号：US11982738
申请日：2007-11-02
Applicant: Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra
Inventor： Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra
IPC: A61K38/00
CPC classification number: A61K39/39558 , A61K45/06 , C07K14/71 , C07K16/18 , C07K2317/52 , C07K2319/30
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
Abstract translation: 在某些方面，本公开涉及以下认识：包含活化素样激酶I（ALK1）多肽的细胞外结构域的配体结合部分的多肽可用于抑制体内血管发生，特别是在血管生成相关的哺乳动物中 疾病 该公开内容还鉴定了ALK1的配体，并证明这些配体具有促血管生成活性，以及抑制受体 - 配体相互作用的抗体。
-
公开(公告)号：US08361957B2
公开(公告)日：2013-01-29
申请号：US13247748
申请日：2011-09-28
Applicant: Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
Inventor： Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
IPC: A61K38/00
CPC classification number: C12N9/12 , A61K38/179 , A61K38/1796 , C07K14/47 , C07K14/475 , C07K2319/30 , C12Q1/6897 , C12Y207/1103
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Abstract translation: 在某些方面，本发明提供用于增加脊椎动物（包括啮齿动物和灵长类动物，特别是人）中红细胞和/或血红蛋白水平的组合物和方法。
-
28.发明授权Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators 有权使用GDF陷阱和促红细胞生成素受体激活剂的组合增加红细胞水平和治疗贫血的方法公开(公告)号：US08216997B2
公开(公告)日：2012-07-10
申请号：US12856420
申请日：2010-08-13
Applicant: Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
Inventor： Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
CPC classification number: C07K14/495 , A61K31/00 , A61K31/454 , A61K31/7068 , A61K38/1709 , A61K38/179 , A61K38/1796 , A61K38/1816 , A61K38/193 , A61K39/39533 , A61K45/06 , C07K14/475 , C07K14/505 , A61K2300/00
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Abstract translation: 在某些方面，本发明提供用于增加脊椎动物（包括啮齿动物和灵长类动物，特别是人）中红细胞和/或血红蛋白水平的组合物和方法。
-
公开(公告)号：US08178488B2
公开(公告)日：2012-05-15
申请号：US12796332
申请日：2010-06-08
Applicant: John Knopf , Jasbir Seehra , Ravindra Kumar
Inventor： John Knopf , Jasbir Seehra , Ravindra Kumar
CPC classification number: C07K16/40 , A61K31/7088 , A61K38/00 , A61K38/1796 , A61P3/00 , A61P3/04 , A61P3/10 , A61P21/00 , C07K14/71 , C07K2319/30 , C12N5/0602
Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
Abstract translation: 在某些方面，本发明提供通过施用ActRIIB信号传导途径的拮抗剂来增加产热脂肪细胞（例如，棕色脂肪细胞或其他表达UCP-1的脂肪细胞）的组合物和方法。 这些拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗肌生成抑制素抗体，抗GDF3抗体，抗淋巴结，抗激活素和抗GDF11抗体。 可以通过引起生热脂肪细胞的增加来治疗各种代谢和其它疾病。
-
公开(公告)号：US20100316644A1
公开(公告)日：2010-12-16
申请号：US12796307
申请日：2010-06-08
Applicant: Jasbir Seehra , Ravindra Kumar
Inventor： Jasbir Seehra , Ravindra Kumar
IPC: A61K39/395 , C07H21/00 , C12N5/10 , C07K14/705 , C07K19/00 , A61K38/16 , A61P3/00 , A61P3/04 , A61P3/10 , A61P5/50 , A61P21/00
CPC classification number: C12N9/12 , A61K38/00 , C07K14/475 , C07K14/71 , C07K2319/30 , C12N2510/02 , C12Y207/1103
Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
Abstract translation: 在某些方面，本发明提供了用于调节（促进或抑制）组织如骨，软骨，肌肉，脂肪，棕色脂肪和/或神经元组织的生长并用于治疗代谢性疾病如糖尿病和肥胖的组合物和方法 ，以及与任何前述组织相关的疾病。
-
-
-
-
-
-
-
-
-
Search Results
90
records
(took 0.042 seconds)
